New pill for cystic fibrosis moves to human testing
NCT ID NCT05090904
First seen Mar 18, 2026 · Last updated Jun 22, 2026 · Updated 8 times
Summary
This study tested an experimental pill called brensocatib in 29 adults with cystic fibrosis. The main goals were to see how the drug behaves in the body and whether it is safe compared to a placebo over 4 weeks. Participants took the pill once daily, and researchers measured drug levels and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
USA001
Gainesville, Florida, 32610, United States
-
USA002
St Louis, Missouri, 63101, United States
-
USA003
Tyler, Texas, 75708, United States
-
USA004
Dallas, Texas, 75390, United States
-
USA006
Cleveland, Ohio, 44195, United States
-
USA008
Cleveland, Ohio, 44106, United States
-
USA009
Charleston, South Carolina, 29425, United States
-
USA011
Boston, Massachusetts, 02115, United States
-
USA016
Augusta, Georgia, 30912, United States
-
USA017
Nashville, Tennessee, 37232, United States
-
USA018
Portland, Oregon, 97239, United States
-
USA022
New York, New York, 10032, United States
-
USA023
Ann Arbor, Michigan, 48109, United States
-
USA025
Glenview, Illinois, 60025, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brensocatib (also called INS1007) oral tablet
What this could lead to
If successful, this could point toward a new treatment option to help control cystic fibrosis lung disease.
What could go wrong
This is a small, early-phase trial focused on safety and drug levels, not on whether the drug improves symptoms. Many drugs fail in later, larger studies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.